Inventiva (NasdaqGM:IVA) Q4 2025 Earnings call March 31, 2026 08:00 AM ET Company ParticipantsAndrew Obenshain - CEODavid Nikodem - Head of Investor RelationsJason Campagna - President of Research And Development and CMOJean Volatier - CFOMichael Yee - Global Head of Biotechnology ResearchConference Call ParticipantsAnna Chien - Equity Research AnalystDominic Pannarale - Equity Research AnalystJasmine Kaur - Healthcare Equity Research AnalystJayed Momin - Equity Research AnalystLucy Codrington - Equity Rese ...

Inventiva (NasdaqGM:IVA) Q4 2025 Earnings call March 31, 2026 08:00 AM ET Company ParticipantsAndrew Obenshain - CEODavid Nikodem - Head of Investor RelationsJason Campagna - President of Research And Development and CMOJean Volatier - CFOMichael Yee - Global Head of Biotechnology ResearchConference Call ParticipantsAnna Chien - Equity Research AnalystDominic Pannarale - Equity Research AnalystJasmine Kaur - Healthcare Equity Research AnalystJayed Momin - Equity Research AnalystLucy Codrington - Equity Rese ...

Inventiva (NasdaqGM:IVA) Q4 2025 Earnings call March 31, 2026 08:00 AM ET Speaker10Good day, and thank you for standing by. Welcome to the Inventiva Full Year 2025 Financial Report webcast and conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To w ...

Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)Cash runway expected until the middle of the first quarter of 20273Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approvedTopline results of NATiV3 Phase ...